Emily Chee is the General Manager – Americas for Novartis Gene Therapies. She has responsibility for the business in the US where Zolgensma was launched in 2019 as well as Canada and Latin America. Emily has worked with Novartis for close to two decades focused on the Oncology business until two years ago when she shifted to Gene Therapies. She has also served many Big Pharma and Biotech clients as a management consultant prior to joining Novartis